Cancer is not a single disease. Different cancers have different biological characteristics, genetic changes, growth patterns, and treatment responses. Because of this, researchers do not assume that an experimental compound that affects one cancer type will necessarily have the same effect on another.
Fenbendazole has been investigated in a range of experimental cancer models, including breast cancer, ovarian cancer, cervical cancer, colorectal cancer, liver cancer, lung cancer, melanoma, and leukemia. Much of this research remains preclinical, meaning it has been conducted in laboratory or animal models rather than in established human cancer treatment trials.
Breast Cancer
Breast cancer has been one of the cancer types investigated in fenbendazole research. Experimental studies have examined breast cancer cells and mouse tumor models to understand whether fenbendazole can influence cancer-cell survival, metabolism, and tumor growth.
One earlier study investigated fenbendazole using EMT6 mouse mammary tumor cells. Although the compound demonstrated cytotoxic effects against the cancer cells under laboratory conditions, the corresponding mouse tumor experiment did not demonstrate significant inhibition of tumor growth. This provides an important example of why results can differ between cell-culture and animal models.
More recent experimental research has also examined fenbendazole in breast cancer models. These studies have continued to investigate mechanisms such as cell-cycle regulation and metabolic changes, adding to the broader preclinical research landscape.
Ovarian Cancer
Ovarian cancer is another area where fenbendazole has received experimental attention. A 2024 study investigated fenbendazole in A2780 and SKOV3 human ovarian cancer cells and found reduced proliferation and increased apoptosis in laboratory experiments.
Researchers also performed an in-vivo xenograft experiment and reported that oral fenbendazole inhibited tumor growth in their mouse ovarian cancer model. The study suggested that the observed effects were associated with pathways involving mitosis, cell-cycle regulation, and apoptosis.
Another ovarian cancer study investigated fenbendazole using different drug-delivery approaches. Interestingly, ordinary oral fenbendazole did not reduce tumor growth in the cell-line xenograft models used in that study. However, fenbendazole incorporated into specially designed PLGA nanoparticles produced significant reductions in tumor weight in xenograft and patient-derived xenograft models.
This research is particularly interesting because it highlights how drug delivery and bioavailability can influence experimental results.
Cervical Cancer
Cervical cancer is one of the more recent areas of fenbendazole research. A 2025 study investigated fenbendazole against cervical cancer cells and cervical cancer stem-cell populations.
Researchers reported reduced proliferation, G2/M cell-cycle arrest, and increased apoptosis in the experimental cell models. They then evaluated fenbendazole in mouse xenograft models and reported significant suppression of tumor growth under the study conditions.
The researchers also investigated cancer stem cells, making this study particularly relevant to research into tumor recurrence and treatment resistance.
Colorectal Cancer
Colorectal cancer has also been included in experimental fenbendazole research. Studies have examined colorectal cancer cell lines to investigate whether fenbendazole can interfere with cellular proliferation and survival.
Research summarized in a recent review includes experimental evidence involving colorectal cancer models, contributing to the broader investigation of fenbendazole across different tumor types.
Liver Cancer
Hepatocellular carcinoma, the most common primary liver cancer, has also been investigated experimentally. Research using hepatocellular carcinoma cells has examined fenbendazole’s effects on cell proliferation and cell-cycle regulation.
Experimental findings have suggested that fenbendazole can influence pathways associated with cell growth and survival. These findings provide another example of how researchers are investigating whether fenbendazole’s biological activity extends across different cancer models.
Lung Cancer
Non-small-cell lung cancer has also appeared in the experimental fenbendazole research landscape. Researchers have investigated the compound’s effects on cancer-cell growth and cellular pathways in laboratory models.
These studies are part of the broader evidence suggesting that fenbendazole can influence several biological processes relevant to cancer cells. However, the evidence for different cancer types varies considerably in depth, and experimental findings should not be interpreted as evidence of clinical effectiveness.
Melanoma and Leukemia
Experimental research has also investigated fenbendazole in models of melanoma and leukemia. These studies contribute to the broader hypothesis that fenbendazole may influence cancer-cell proliferation and survival through multiple biological pathways.
However, the amount and strength of evidence are not the same for every cancer type. Some cancers have been investigated using both cell and animal models, while others have primarily been studied in laboratory systems.
Are the Findings Consistent Across Cancer Types?
The answer is not completely. Some experimental models have produced encouraging findings, including reduced cancer-cell proliferation, increased apoptosis, and tumor-growth suppression in certain animal models. Other studies have produced weaker effects or no measurable tumor-growth inhibition.
The ovarian cancer research provides a useful example. One study reported tumor-growth inhibition using oral fenbendazole, while another found that ordinary oral fenbendazole did not reduce tumor growth but observed activity after using a nanoparticle delivery system.
PubMed reference – Ovarian cancer →
PubMed reference – Nanoparticle delivery →
This variation does not necessarily mean that the research is contradictory in every respect. Different studies can use different cancer cell lines, animal models, doses, treatment schedules, formulations, and methods of drug delivery. These differences can substantially influence experimental outcomes.
Why Might Different Cancers Respond Differently?
Cancer cells are biologically diverse. Even cancers that originate in the same organ can contain different genetic alterations, metabolic characteristics, signaling pathways, and levels of treatment sensitivity.
Fenbendazole research has proposed effects on several processes—including microtubules, glucose metabolism, oxidative stress, mitochondrial function, cell-cycle regulation, and apoptosis.
Differences in these pathways between cancer types could potentially influence how individual experimental models respond. Understanding these differences is an important area for future research.
Key Takeaway
Fenbendazole has been investigated across multiple cancer models, with findings that vary depending on the cancer type, experimental system, formulation, dose, and method of delivery. Some laboratory and animal studies have reported biological or tumor-growth effects, while others have not. Importantly, these preclinical findings do not establish fenbendazole as an effective cancer treatment in humans.